Factors Influencing Outcome Post–Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges

Aim  Radium-223 has been the first-approved targeted Alpha therapy agent. We retrospectively assessed different factors influencing the overall survival (OS) and patient management. Setting and Design Thirty-two metastatic castration-resistant prostate cancer (mCRPC) patients' hematological par...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhoil, Amit, Chuah, Phei Shan, Seshadri, Nagabhushan, Vinjamuri, Sobhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665971/
https://www.ncbi.nlm.nih.gov/pubmed/36398304
http://dx.doi.org/10.1055/s-0042-1750015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665971/
https://www.ncbi.nlm.nih.gov/pubmed/36398304
http://dx.doi.org/10.1055/s-0042-1750015

Ejemplares similares